Anzeige
Mehr »
Mittwoch, 11.02.2026 - Börsentäglich über 12.000 News
Breaking News: Pacifica meldet neue hochgradige Entdeckung und genau deshalb kann der Markt das nicht ignorieren
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
820 Leser
Artikel bewerten:
(2)

Veeva Systems: LTS Advances Quality Oversight with Veeva Vault QMS

Leading pharmatech unifies quality processes for greater efficiency, collaboration, and compliance

BARCELONA, Spain, Sept. 14, 2023 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that LTS LOHMANN Therapie-Systeme AG ("LTS"), a leading pharmaceutical technology company, is partnering with Veeva MedTech to advance its quality operations. LTS will use Veeva Vault QMS to improve process control and visibility, align global production sites, and increase audit readiness.

Veeva Systems

"As we continue to grow, we need a modern, scalable, and user-friendly quality management tool to harmonize and advance our quality processes across the organization," said Dr. Heike Barnikow-Bock, corporate vice president operations, quality projects and consulting, LTS. "With Veeva Vault QMS, we will strengthen oversight and GxP compliance while aligning with the quality requirements of our customers."

"Veeva's open collaboration and flexibility to meet our needs make it the perfect partner," said Christian Langer, corporate senior vice president of global quality at LTS. "The team's breadth of experience and focus on execution made completing this project in such a short amount of time possible."

With headquarters in Germany and four sites in North America, Europe, and Asia, LTS develops and manufactures drug delivery systems, such as transdermal patches, oral thin films, and wearable drug delivery devices. Vault QMS will help LTS manage and track quality processes, such as deviations, complaints, lab incidents, corrective and preventive actions, and change control. By improving its quality management processes, LTS can provide greater value to its partners and drive better patient outcomes, which aligns with the LTS purpose: "We CARE. We CREATE. We DELIVER."

"Veeva Vault QMS helps companies like LTS simplify quality processes for better efficiency while ensuring ongoing inspection readiness," said Patrik Brehm, director of quality strategy for Veeva MedTech in Europe. "Veeva is proud to partner with the team to help streamline its quality operations."

Veeva MedTech offers unified, connected cloud software solutions to help deliver medical devices and diagnostics to patients in need. It includes Veeva Vault products across research and development and commercial to help speed the total product development lifecycle for medtech companies.

Vault QMS is part of Vault Quality Suite, which brings together quality systems and processes on a single cloud platform to enable efficient quality management.

About Veeva Systems

Veeva is the global leader in cloud software for the life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,000 customers, ranging from the world's largest biopharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit veeva.com/eu.

Veeva Forward-looking Statements

This release contains forward-looking statements regarding Veeva's products and services and the expected results or benefits from use of our products and services. These statements are based on our current expectations. Actual results could differ materially from those provided in this release and we have no obligation to update such statements. There are numerous risks that have the potential to negatively impact our results, including the risks and uncertainties disclosed in our filing on Form 10-Q for the period ended July 31, 2023, which you can find here (a summary of risks which may impact our business can be found on pages 38 and 39), and in our subsequent SEC filings, which you can access at sec.gov.

Contact:

Jeremy Whittaker
Veeva Systems
+49-695-095-5486
jeremy.whittaker@veeva.com

Logo - https://mma.prnewswire.com/media/1488285/Veeva_Systems_Logo.jpg

Cision View original content:https://www.prnewswire.co.uk/news-releases/lts-advances-quality-oversight-with-veeva-vault-qms-301926604.html

© 2023 PR Newswire
Favoritenwechsel
Das Börsenjahr 2026 ist für viele Anleger ernüchternd gestartet. Tech-Werte straucheln, der Nasdaq 100 tritt auf der Stelle und ausgerechnet alte Favoriten wie Microsoft und SAP rutschen zweistellig ab. KI ist plötzlich kein Rückenwind mehr, sondern ein Belastungsfaktor, weil Investoren beginnen, die finanzielle Nachhaltigkeit zu hinterfragen.

Gleichzeitig vollzieht sich an der Wall Street ein lautloser Favoritenwechsel. Während viele auf Wachstum setzen, feiern Value-Titel mit verlässlichen Cashflows ihr Comeback: Telekommunikation, Industrie, Energie, Pharma – die „Cashmaschinen“ der Realwirtschaft verdrängen hoch bewertete Hoffnungsträger.

In unserem aktuellen Spezialreport stellen wir fünf Aktien vor, die genau in dieses neue Marktbild passen: solide, günstig bewertet und mit attraktiver Dividende. Werte, die nicht nur laufende Erträge liefern, sondern auch bei Marktkorrekturen Sicherheit bieten.

Jetzt den kostenlosen Report sichern – bevor der Value-Zug 2026 endgültig abfährt!

Dieses exklusive PDF ist nur für kurze Zeit gratis verfügbar.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.